AOP Health Appoints John Kimmet as U.S. General Manager

Veteran pharmaceutical executive to lead AOP Health’s U.S. expansion and commercial launch of Rapiblyk™

AOP Orphan Pharmaceuticals GmbH (AOP Health), a global leader in integrated therapy solutions for rare diseases and critical care, is pleased to announce the appointment of John Kimmet as U.S. General Manager. John brings more than 25 years of leadership experience, with a strong track record of success in the pharmaceutical industry.

John has held senior executive roles at leading pharmaceutical companies, including Bristol-Myers Squibb / Celgene and Eagle Pharmaceuticals. Most recently, he served as a Strategic Advisor to the Board at Copilot Hub Services. His strategic insights and operational expertise make him uniquely suited to lead AOP Health’s expansion into the U.S. market.

As U.S. General Manager, John will lead critical efforts to set up and grow AOP Health’s U.S. presence, with a focus on overseeing the commercial launch of Rapiblyk™ (landiolol), an ultra-short-acting beta-1 selective adrenergic receptor blocker for critical care use. His role will also establish the infrastructure necessary to support healthcare professionals and the patients they serve.

To drive this effort, AOP Health is actively building out its U.S. field organization. The company has hired a team of Medical Science Liaisons, National Account Managers, and Key Account Managers to provide dedicated support to providers nationwide.

About Rapiblyk™ (landiolol)

Rapiblyk™ is a short-acting beta-1 selective adrenergic receptor antagonist, with a beta-1/beta-2 selectivity ratio of 255. It enables rapid heart rate control without significant blood pressure reduction. It is intended for use in intensive care, perioperative, emergency, and cardio-thoracic units. It is not indicated for chronic arrhythmia management.

INDICATION

Rapiblyk™ is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Rapiblyk™ is contraindicated in patients with:

• Severe sinus bradycardia, sick sinus syndrome, or >1st-degree AV block
• Decompensated heart failure
• Cardiogenic shock
• Pulmonary hypertension
• Known hypersensitivity to landiolol or formulation components

WARNINGS AND PRECAUTIONS

Includes risk of hypotension, bradycardia, cardiac failure, bronchospasm, masking of hypoglycemia symptoms, infusion site reactions, worsening of Prinzmetal’s angina, complications in pheochromocytoma, peripheral vascular disease, abrupt withdrawal effects, hyperkalemia, metabolic acidosis, and unresponsiveness to epinephrine in hypersensitivity reactions.

ADVERSE REACTIONS

Most common adverse event: Hypotension (9.9% vs. 1% in placebo).
Please consult the full Prescribing Information for Rapiblyk™: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf

About AOP Health

AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust" the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company’s actions.

Forward-Looking Statement
This press release contains “forward-looking statements,” including statements relating to AOP Health Group’s (“AOP Health”) financial position and long-term outlook on its business, including the commercialization of its approved product and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to AOP Health’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including AOP Health’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause AOP Health’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. AOP Health undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Further inquiries:

Mag. Nina Roth, MAS
Director Corporate Communications
nina.roth[at]aop-health.com
+43-676-3131509

From the US: 011-43-676-3131509